FDA Panel Backs Shingles Vaccine for People 60 and Older

BETHESDA, MD. — The available data clearly support the safety and effectiveness of a herpes zoster vaccine for people ages 60 and older, the age group that made up most of the participants in clinical trials, a 14-member federal advisory panel unanimously agreed at a meeting last month.